The DOI matches its Crossref record; the references it cites are not checked yet.
Leucocyte and eosinophil counts predict progression‐free survival in relapsed or refractory classical Hodgkin Lymphoma patients treated with PD 1 inhibition
Open accessAbstract
The British Journal of Haematology publishes original research papers in clinical, laboratory and experimental haematology. The Journal also features annotations, reviews, short reports, images in haematology and Letters to the Editor.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
An elevated eosinophil count prior to treatment was associated with longer overall survival in several studies.
“Furthermore, an elevated eosinophil count prior to treatment was associated with longer overall survival in several studies.8–12”
From Moderate-to-severe eosinophilia induced by treatment with immune checkpoint inhibitors: 37 cases from a national reference center for hypereosinophilic syndromes and the French pharmacovigilance database (2020) · cites this paper as [12]
The Abstract reports that a higher pretreatment relative eosinophil count was associated with a lower risk of progression in patients with relapsed or refractory Hodgkin lymphoma. It also mentions earlier correlations between baseline eosinophil counts and survival in melanoma. This paper measures progression-free survival, however, and does not establish the claimed association with longer overall survival. (LLM, conf=0.88)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
The citation lists haven’t been fetched yet
References 10 · Cited by 27
Metadata
- Authors
- Hude, I., Sasse, S., Bröckelmann, P. J., von Tresckow, B., Momotow, J., Engert, A., & Borchmann, S.
- Affiliations
- University Hospital Centre Zagreb (HR)
- University Hospital Cologne (DE)
- German Hodgkin Study Group (GHSG) Department I of Internal Medicine University Hospital Cologne Cologne Germany
- Corresponding author
- Borchmann, Sven
- Venue
- British Journal of Haematology
- Publisher
- Wiley
- Published
- 2017-04-25
- Volume
- 181
- Issue
- 6
- Pages
- 837-840
- ISSN
- 0007-1048 (ISSN-L)
- 1365-2141
- OpenAlex
- W2609753980
- Semantic Scholar
- f9c7837b32f45b0a899633be304785b82e3034ff
- Cited by
- 27
- References
- 10
- Citations by year
- 2025: 2 · 2024: 2 · 2023: 3 · 2022: 5 · 2021: 4 · 2020: 6 · 2019: 1 · 2018: 3 · 2017: 1
- FWCI
- 2.36
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- British Journal of Haematology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- EHA
- Cologne Fortune Grant (181/2016)
- Bristol-Myers Sqibb
- Topics
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- classical Hodgkin lymphoma, relapsed/refractory disease, anti-PD-1 therapy, white blood cell count, eosinophil count, progression-free survival, prognostic factors, immune checkpoint inhibitors
- MeSH terms
- Nivolumab, Adult, Eosinophils, Female, Hodgkin Disease, Humans, Leukocyte Count, Male, Middle Aged, Predictive Value of Tests, Retrospective Studies, Survival Rate, Hematopoietic Stem Cell Transplantation, Disease-Free Survival, Programmed Cell Death 1 Receptor, Autografts
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
